BioAegis Therapeutics Announces Publication in “Clinical Infectious Diseases” Linking Depleted Plasma Gelsolin Concentrations at Admission to Severe Pneumonia Outcomes in CDC-Sponsored “Etiology of Pneumonia in the Community (EPIC)” Study
01 févr. 2019 10h53 HE
|
BioAegis Therapeutics
MORRISTOWN, N.J., Feb. 01, 2019 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc. announced the publication of a paper in Clinical Infectious Disease—a journal of the Infectious Disease Society of...
Fedora Pharmaceuticals and Meiji Seika Pharma Sign Basic Agreement to Establish NacuGen Therapeutics Inc., a Joint Venture to Develop and Commercialize Nacubactam for Bacterial Infections
07 janv. 2019 09h00 HE
|
Nacugen Therapeutics, Inc.
EDMONTON, Alberta and Tokyo , Jan. 07, 2019 (GLOBE NEWSWIRE) -- Fedora Pharmaceuticals, Inc. (headquarters: Edmonton, Alberta, Canada; Chief Executive Officer: Christopher G. Micetich, hereinafter...
New Genomic Technology Advances Fight Against Global Health Threat of Antibiotic Resistance
06 déc. 2018 09h14 HE
|
Phase Genomics
SEATTLE, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Phase Genomics, the leader in proximity-ligation genome assembly technology released an antimicrobial resistance (AMR) study led by researchers from the...
BioAegis Therapeutics Enrolls First Patients in Phase 1b/2a Community-Acquired Pneumonia Study and Raises $4 MM in Equity Round
18 sept. 2018 08h52 HE
|
BioAegis Therapeutics
MORRISTOWN, N.J., Sept. 18, 2018 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc. announced that it has begun patient enrollment in a Phase 1b/2a study of recombinant plasma gelsolin (rhu-pGSN) in...
HP Delivers Innovations to Public Health with New CDC Pilot Program
27 août 2018 11h01 HE
|
HP Inc.
News highlights CDC launches HP pilot program with the purchase of HP BioPrinters for four regional labs in New York, Minnesota, Tennessee, and Wisconsin.HP BioPrinters, with inkjet printing...
Summit Unveils Second Novel Target for Gonorrhoea at ASM Microbe 2018
11 juin 2018 07h00 HE
|
Summit Therapeutics plc
Highlights the Power of the Discuva Platform to Identify Novel Antibiotic Targets OXFORD, United Kingdom and CAMBRIDGE, Mass., June 11, 2018 (GLOBE NEWSWIRE) -- Summit Therapeutics plc...
Avivagen Reports Positive Proof of Concept in Preventing C. Difficile Infection
10 avr. 2017 07h42 HE
|
Avivagen Inc.
OTTAWA, April 10, 2017 (GLOBE NEWSWIRE) -- Avivagen Inc. (TSXV:VIV) (OTC Pink:CHEXF) (Avivagen or the Corporation), a company with a proven and commercially-ready, patent-protected product...
Fedora Pharmaceuticals Receives Support from the Government of Canada to Battle Antimicrobial Resistance with Novel Pipeline of Antibiotic Candidates
16 janv. 2017 10h51 HE
|
Fedora Pharmaceuticals, Inc.
EDMONTON, Alberta , Jan. 16, 2017 (GLOBE NEWSWIRE) -- Fedora Pharmaceuticals, Inc. announced they have received non-refundable financial contribution from the National Research Council of Canada’s...